1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )TABLE 2:MR Imaging and SPECT findings in nine patients with DAVF hyperintensity on T2-Weighted MR Images
Patient Before Treatmen Findings After Treatment Findings Outcome T2-Weighted MR Imaging SPECT T2-Weighted MR Imaging SPECT At Rest With Acetazolamide At Rest With Acetazolamide Type 2a 12 Hyperintensity Hypoperfusion Preserved T2-normalization at 1 mo Normal Not done Good 13 Hyperintensity Hypoperfusion Preserved T2-normalization at 2 wk Normal Not done Good 14 Hyperintensity Hypoperfusion Preserved T2-normalization at 2 wk Normal Not done Good 15 Hyperintensity Hypoperfusion Preserved T2-normalization at 1 wk Normal Not done Good 16 Hyperintensity Hypoperfusion Preserved T2-normalization at 3 wk Normal Not done Good 17 Hyperintensity Hypoperfusion Preserved T2-normalization at 2 wk Normal Not done Good 18 Hyperintensity Hypoperfusion Preserved T2-normalization at 3 wk Normal Not done Good Type 2b 19 Hyperintensity Hypoperfusion Non-preserved T2-hyperintensity continued, subcortical hemorrhage Hypoperfusion, peripheral hyperperfusion Non-preserved Poor 20 Hyperintensity Hypoperfusion Non-preserved T2-hyperintensity continued Hypoperfusion Non-preserved Poor 21 Hyperintensity Hypoperfusion Non-preserved T2-hyperintensity continued Hypoperfusion Non-preserved Poor 22 Hyperintensity Hypoperfusion Non-preserved T2-hyperintensity continued Hypoperfusion Non-preserved Poor